Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial

Condition:   Acute Coronary Syndrome
Interventions:   Drug: MDCO-216;   Drug: Placebo
Sponsors:   The Medicines Company;   The Cleveland Clinic
Recruiting - verified February 2016

Increasing Exercise and Decreasing Sedentary Behavior Among Patients in a Cardiac Rehabilitation Clinic

Conditions:   Acute Coronary Syndrome;   Heart Failure;   Other Cardiac Conditions Among Cardiac Rehabilitation Participants
Interventions:   Other: B-MOBILE-CARDIAC smartphone application;   Behavioral: Cardiac rehabilitation as usual
Sponsor:   The Miriam Hospital
Not yet recruiting - verified February 2016

Rivaroxaban ACS Specialist Cohort Event Monitoring Study

Condition:   Acute Coronary Syndrome
Intervention:   Other: This is a non-interventional study
Sponsor:   Drug Safety Research Unit, Southampton, UK
Recruiting - verified February 2016

Accelerated Rule Out of Myocardial Infarction

Condition:   Myocardial Infarction
Intervention:   Procedure: Accelerated, combined biomarker rule-out strategy for MI
Sponsor:   Aarhus University Hospital Skejby
Recruiting - verified February 2016

Knowledge Translation for Patients With Acute Coronary Syndromes

Condition:   Acute Coronary Syndromes
Intervention:   Behavioral: knowledge translation
Sponsors:   Montreal General Hospital;   Sanofi;   Canadian Institutes of Health Research (CIHR);   Fonds de la Recherche en Santé du Québec
Completed - verified January 2016

Hydroxychloroquine in Acute Coronary Syndrome: Prevention of Recurrent Cardiovascular Events

Conditions:   Myocardial Infarction;   Acute Coronary Syndrome;   Inflammation;   Hydroxychloroquine;   Antirheumatic Agents;   Cardiovascular Diseases;   Angina, Unstable
Interventions:   Drug: Hydroxychloroquine;   Drug: Placebo
Sponsors:   Helsinki University Central Hospital;   Finnish Foundation for Cardiovascular Research;   Orion Corporation, Orion Pharma
Not yet recruiting - verified February 2016

Clinical Performance Evaluation of AQT90 FLEX TnI and TnT

Condition:   Myocardial Infarction
Intervention:  
Sponsor:   Radiometer Medical ApS
Recruiting - verified January 2016

Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)

Condition:   Cardiovascular Diseases
Interventions:   Drug: Ticagrelor;   Drug: Prasugrel;   Drug: Clopidogrel
Sponsors:   Erasmus Medical Center;   Covance
Recruiting - verified January 2016

Coronary Artery Aneurysm Registry

Condition:   Coronary Artery Aneurysm
Intervention:  
Sponsor:   St Carlos Hospital, Madrid, Spain
Recruiting - verified September 2015

ALLiance for sEcondary PREvention After an Episode of Acute Coronary Syndrome (ALLEPRE)

Condition:   Acute Coronary Syndrome
Interventions:   Behavioral: Nurse-led Intensive Secondary Prevention Programme;   Behavioral: Usual Treatment
Sponsor:   Azienda Ospedaliero-Universitaria di Parma
Recruiting - verified February 2016

ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts

Conditions:   Coronary Artery Disease;   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Aspirin 100 mg;   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   University Hospital of Ferrara
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified February 2016

Prospective Registry of Acute Coronary Syndromes in Ferrara

Condition:   Acute Coronary Syndromes
Intervention:   Other: prospective collection of data and follow-up
Sponsor:   University Hospital of Ferrara
Recruiting - verified January 2016

Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients

Condition:   Acute Coronary Syndrome (ACS)
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified February 2016

An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome,
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Recruiting - verified January 2016

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

Condition:   ST Elevation Acute Myocardial Infarction
Interventions:   Drug: Exenatide;   Other: Remote Ischemic Conditioning (RIC);   Drug: Placebo
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Not yet recruiting - verified January 2016

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Conditions:   Coronary Artery Disease;   Atherosclerosis, Coronary;   Myocardial Ischemia;   Ischemic Heart Disease;   Acute Coronary Syndrome;   Angina Pectoris
Interventions:   Device: Orsiro DES;   Device: Xience DES
Sponsors:   Biotronik, Inc.;   Biotronik AG;   Harvard Clinical Research Institute;   Medstar Research Institute
Recruiting - verified February 2016

Frailty in Elderly Patients Receiving Cardiac Interventional Procedures

Condition:   Frailty
Intervention:   Other: frailty evaluation
Sponsor:   University Hospital of Ferrara
Recruiting - verified September 2015

Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes

Conditions:   Chronic Obstructive Pulmonary Disease;   Acute Coronary Syndromes
Intervention:   Other: screening test
Sponsor:   University Hospital of Ferrara
Active, not recruiting - verified September 2015

Plaque Stabilization and Restoration by Bioresorbable Vascular Scaffold

Condition:   Vulnerable Plaque
Intervention:   Device: Bioresorbable vascular scaffold
Sponsor:   Canisius-Wilhelmina Hospital
Recruiting - verified January 2016

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 2015

Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified January 2016

Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease

Condition:   Kawasaki Disease
Intervention:   Drug: Aspirin
Sponsor:   Chang Gung Memorial Hospital
Enrolling by invitation - verified May 2013

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

Condition:   Myocardial Injury
Interventions:   Drug: ticagrelor;   Drug: aspirin
Sponsors:   The Cleveland Clinic;   AstraZeneca
Recruiting - verified January 2016

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2016

Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

Condition:   Sickle Cell Disease
Intervention:   Drug: Hydroxyurea
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2015

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Losmapimod 7.5 mg twice daily;   Drug: Placebo twice daily
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Recruiting - verified January 2016

Impact of Nasal High-flow vs Venturi Mask Oxygen Therapy on Weaning Outcome: a Multicenter, Randomized, Controlled Trial

Conditions:   Weaning Failure;   Acute Respiratory Failure
Interventions:   Device: Optiflow (Fisher & Paykel Healthcare);   Device: Venturi mask
Sponsors:   Catholic University of the Sacred Heart;   Fisher and Paykel Healthcare
Recruiting - verified February 2016

Early Predictive Factors of Cardiac and Cerebral Involvement in TMA

Conditions:   Thrombotic Microangiopathy,;   Thrombotic Thrombocytopenic Purpura,
Intervention:   Other: Biological and imaging investigations
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified February 2016

Essential Hypotension and Adaptability Registry

Conditions:   Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Intervention:  
Sponsor:   CES University
Recruiting - verified February 2016

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Conditions:   Rivaroxaban;   Cancer-associated Thrombosis;   Recurrence;   Bleeding
Intervention:   Drug: Rivaroxaban
Sponsors:   Seoul National University Hospital;   Korean Society of Hematology Thrombosis Working Party
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified February 2016

Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)

Conditions:   Hemophagocytic Lymphohistiocytosis;   Chronic Active Epstein-Barr Virus Infection;   Chronic Granulomatous Disease;   HIGM-1;   Leukocyte Adhesion Deficiency;   IPEX
Intervention:   Biological: Hematopoietic Stem Cell Transplant
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2016

Procedures and Follow-up of Percutaneous Tracheostomy in Intensive Care Unit

Conditions:   Acute Respiratory Failure;   Neurological Disease;   Heart Failure
Intervention:   Procedure: Percutaneous tracheostomy
Sponsor:   University of Genova
Recruiting - verified February 2016

Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement Diabetics Presenting With Acute Coronary Syndrome

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity stent
Sponsor:   Emory University
Active, not recruiting - verified February 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified February 2016

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified January 2016

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia
Interventions:   Procedure: cardiac catheterization;   Procedure: coronary artery bypass graft surgery;   Procedure: percutaneous coronary intervention;   Behavioral: Lifestyle;   Drug: Medication
Sponsors:   New York University School of Medicine;   New York University;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   Albany Stratton VA Medical Center;   Cedars-Sinai Medical Center;   Columbia University;   Duke University;   East Carolina University;   Emory University;   Harvard University;   Massachusetts General Hospital;   Montreal Heart Institute;   University of British Columbia;   University of Missouri, Kansas City;   Vanderbilt University
Recruiting - verified January 2016

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Conditions:   Infection;   Hypertension;   Pain;   Reflux;   Edema;   Hyperlipidemia;   Hypotension;   Hypercholesterolemia;   Sedation;   Anxiolysis;   Benzodiazepine Withdrawal;   Bipolar Disorder;   Autistic Disorder;   Schizophrenia;   Influenza Treatment or Prophylaxis;   Acute Decompensated Heart Failure;   Stable Angina;   Life-threatening Fungal Infections;   Nosocomial Pneumonia;   Community Acquired Pneumonia;   Acute Bacterial Exacerbation of Chronic Bronchitis;   Complicated Skin and Skin Structure Infections;   Uncomplicated Skin and Skin Structure Infections;   Chronic Bacterial Prostatitis;   Complicated Urinary Tract Infections;   Acute Pyelonephritis;   Uncomplicated Urinary Tract Infections;   Inhalational Anthrax (Post-Exposure);   Infantile Hemangioma;   Withdrawal;   Inflammation;   Bacterial Septicemia;   Cytomegalovirus Retinitis;   Herpes Simplex Virus;   Adenovirus;   Brain Swelling;   Airway Swelling;   Adrenal Insufficiency;   Anxiety;   Nausea;   Vomiting;   Convulsions;   Muscle Spasms;   Seizures;   Epilepsy;   Bartonellosis;   Brucellosis;   Cholera;   Plague;   Psittacosis;   Q Fever;   Relapsing Fever;   Rocky Mountain Spotted Fever;   Trachoma;   Tularemia;   Typhus Fever;   Bronchospasm;   Cardiac Arrest;   Hypersensitivity Reaction;   Cyanide Poisoning;   Acute Bacterial Sinusitis;   Bacterial Meningitis;   Sepsis;   Gastroparesis;   Opioid Addiction;   Migraines;   Headaches
Intervention:   Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Sponsors:   Daniel Benjamin;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   The EMMES Corporation;   OpAns, LLC
Recruiting - verified February 2016

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Conditions:   B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2016

Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for High Risk Acute Variceal Bleeding in Cirrhotic Patients

Conditions:   Decompensated Cirrhosis;   Bleeding Varices
Interventions:   Procedure: Transjugular intrahepatic portosystemic shunt;   Drug: Non-selective beta blocker + Endoscopic treatment
Sponsor:   Fourth Military Medical University
Recruiting - verified February 2016

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients

Conditions:   Death;   Stroke;   Low Cardiac Output Syndrome;   Myocardial Infarction;   Renal Failure;   Pulmonary Failure
Interventions:   Other: Remote ischemic preconditioning stimulus;   Other: control
Sponsor:   Queen's University
Completed - verified February 2016

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

Condition:   Saphenous Vein Graft Atherosclerosis
Interventions:   Device: Bare Metal Stent;   Device: Drug-Eluting Stent;   Drug: Blinded clopidogrel;   Drug: Placebo;   Drug: Thienopyridine (open-label)
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified February 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
Interventions:   Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified October 2015

Comparative Evaluation of Albumin and Starch Effects in Acute Lung Injury (ALI)

Conditions:   Lung Injury, Acute (ALI);   Respiratory Distress Syndrome, Acute (ARDS)
Interventions:   Drug: 5% human albumin;   Drug: 6% hetastarch
Sponsor:   Emory University
Terminated - verified January 2016

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Condition:   Coronary Heart Disease
Interventions:   Drug: Evidence-based medical care for Acute Coronary Syndrome;   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury

Conditions:   Respiratory Distress Syndrome, Adult;   Head Injuries, Closed;   Shock;   Shock, Traumatic
Interventions:   Drug: Hypertonic Saline-Dextran Solution;   Drug: Lactated Ringer's Solution
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2007

Ibuprofen in Sepsis Study

Conditions:   Acute Respiratory Distress Syndrome;   Lung Diseases;   Shock, Septic
Intervention:   Drug: ibuprofen
Sponsors:   Vanderbilt University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2016